Salenger Sack Kimmel & Bavaro logo

SSKB News

2026 Legal Forecast: Lawsuits That Could Shape Corporate Accountability That You May Qualify For

Collage of a gavel, insulin pen, spilled white powder, phone with social media likes, Roblox logo, and an intrauterine device, representing various topical issues and debates.

As we head into 2026, several major lawsuits are reaching pivotal moments that could reshape mass tort litigation, product liability law, and corporate accountability across the United States. From billion-dollar talc verdicts to newly formed multidistrict litigations (MDLs) involving prescription drugs, medical devices, and social media platforms, courts are increasingly sending a clear message: juries—not corporations—should decide questions of safety, harm, and responsibility.

Below is a clear look at the most important lawsuits to watch in 2026 and why they matter.

2026 at a Glance: Key Lawsuits to Watch

In 2026, courts will hear bellwether trials in the Paragard IUD MDL, continue appeals and trials in billion-dollar talc cancer cases against Johnson & Johnson, advance a new GLP-1 vision-loss MDL, and move forward with social media addiction and Roblox sexual abuse litigation involving thousands of plaintiffs nationwide.

Talc Lawsuits Against Johnson & Johnson: Billion-Dollar Verdicts Fuel Momentum

Talc litigation reached a historic turning point in late 2025, with juries delivering some of the largest verdicts ever seen in asbestos-related cancer cases.

Major Talc Verdicts

  • Baltimore, MD (December 2025):
    A jury awarded over $1.5 billion to a woman who developed mesothelioma after long-term use of Johnson & Johnson’s talc products—marking the largest single-plaintiff verdict against the company to date.
  • California (October 2025):
    $966 million awarded to the family of a woman who died from mesothelioma linked to asbestos-contaminated talc.
  • Los Angeles, CA (December 2025):
    $40 million awarded to two women diagnosed with ovarian cancer after years of talc use.

Johnson & Johnson’s Response

Johnson & Johnson continues to deny liability, insisting its talc products were safe and asbestos-free. The company has announced plans to appeal these verdicts, calling them unconstitutional.

Notably:

  • Talc-based baby powder sales ended in North America in 2020
  • Global talc sales ended in 2023, replaced by cornstarch-based products

What to expect in 2026:
Additional trials, continued appeals, and increasing pressure for large-scale settlement discussions as jury verdicts continue to favor plaintiffs.

Were you or a loved one diagnosed with mesothelioma or ovarian cancer after using talcum powder?

Speak with an experienced asbestos and cancer litigation team.

GLP-1 Weight-Loss Drugs & Vision Loss (NAION): New MDL Formed

A second federal Multidistrict Litigation (MDL No. 3176) involving GLP-1 medications was recently established in December 2025 for lawsuits alleging the drugs cause vision loss. This new MDL is expected to be a major focus in 2026, alongside an existing MDL (MDL No. 3094) concerning severe gastrointestinal injuries. 

As of December 2025, nearly 2,947 lawsuits have been filed by patients alleging they suffered Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)—a sudden and often permanent form of vision loss—after taking GLP-1 drugs.

Key Facts

  • Defendants include Eli Lilly and Company and Novo Nordisk
  • Federal judges approved consolidation into an MDL
  • Companies supported consolidation while maintaining the drugs are “safe and effective”

Why MDL Consolidation Matters

MDLs streamline discovery, ensure all parties have access to the same evidence, and help courts determine whether bellwether trials or global settlements are appropriate.

What to expect in 2026:
Expert discovery, plaintiff fact sheets, and early bellwether planning as courts examine the scientific link between GLP-1 drugs and vision loss.

Experienced sudden vision loss after Ozempic®, Wegovy®, Mounjaro®, or Rybelsus®?

Our attorneys are actively investigating NAION claims nationwide.

Roblox Sexual Abuse Lawsuits: MDL Moves Forward

In December 2025, federal courts consolidated 80 lawsuits alleging child sexual abuse and exploitation on the Roblox platform.

  • Platform: Roblox
  • Judge: Richard Seeborg
  • Court: Northern District of California

The cases are now proceeding through consolidated discovery, with bellwether trials expected if a global settlement is not reached first.

What to expect in 2026:
Review of internal safety policies, expert testimony on child-protection failures, and heightened scrutiny of online gaming platforms.

Was your child harmed while using Roblox or another online platform?

Confidential consultations are available for families nationwide.

Social Media Addiction Lawsuits: Bellwether Trials & CEO Scrutiny in 2026

In 2026, social media addiction lawsuits will move into bellwether trials, testing claims that platforms like Instagram, TikTok, and Snapchat were intentionally designed to addict children and teenagers. These early trials—expected to begin with individual injury cases, followed by school district lawsuits—could significantly shape nationwide settlement negotiations.

Defendants, including Meta Platforms, ByteDance, Snap, and Google, argue that Section 230 of the Communications Decency Act shields them from liability. Courts, however, have rejected that defense where claims focus on addictive design features—such as algorithms, push notifications, and infinite scrolling—rather than user-generated content.

As these cases advance, social media executives are expected to be questioned under oath, with discovery and testimony examining what company leadership knew about the mental-health risks to youth and why addictive features remained in place.

Paragard IUD Lawsuits: Bellwether Trials Begin January 2026

Thousands of lawsuits allege the Paragard IUD (copper intrauterine device) has a design defect causing its plastic arms to break during removal, leading to severe pain, infection, organ damage, infertility, and requiring surgeries like hysterectomies. These cases are consolidated into a Multi-District Litigation (MDL) in Georgia, with bellwether trials (test cases) starting in 2026, after a judge dismissed some design defect claims but allowed failure-to-warn claims to proceed. Defendants include CooperSurgical and Teva Pharmaceuticals, who are accused of failing to warn users about these serious risks, with plaintiffs seeking compensation for medical bills, lost wages, and pain/suffering.  

Bellwether Trial Schedule

  • Braxton v. Teva: January 20, 2026
  • Second trial: March 3, 2026
  • Third trial: May 11, 2026

Judge: Leigh Martin May

Allegations

Plaintiffs allege the copper IUD’s plastic arms:

  • Become brittle over time
  • Break during removal
  • Embed in organs
  • Cause infertility and chronic pain
  • Require surgical intervention, including laparoscopy or hysterectomy

Defendants include Teva Pharmaceuticals and CooperSurgical.

With over 3,600 active cases, these bellwether trials are expected to strongly influence settlement negotiations.

Did your Paragard IUD break or require surgical removal?

Our firm is actively reviewing Paragard claims nationwide.

Why 2026 Matters for Injury Victims

2026 is shaping up to be a defining year for mass tort litigation. Bellwether trials, billion-dollar verdicts, and newly formed MDLs will help determine settlement values, corporate accountability, and whether injured individuals gain meaningful access to compensation.

Across pharmaceuticals, medical devices, consumer products, and technology platforms, courts are signaling a clear message: claims of serious harm deserve to be heard by juries.

About Salenger, Sack, Kimmel & Bavaro, LLP

Salenger, Sack, Kimmel & Bavaro (SSKB) represents individuals and families harmed by dangerous products, defective drugs and medical devices, and institutional failures nationwide. Our attorneys are actively litigating major mass torts and MDLs while providing personalized, client-focused representation.

Call Me
We'll call you!
Consent*
Email Us
Send any details you'd like, and we'll get back to you shortly.
Consent*